| scholarly article | Q13442814 |
| P50 | author | Thomas Burris | Q67982842 |
| Theodore M Kamenecka | Q88039489 | ||
| P2093 | author name string | Michael J Chalmers | |
| Patrick R Griffin | |||
| Mi Ra Chang | |||
| Mark Rance | |||
| Douglas J Kojetin | |||
| Travis S Hughes | |||
| Scott Novick | |||
| Dana S Kuruvilla | |||
| Bruce A Johnson | |||
| P2860 | cites work | Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA | Q24655111 |
| THESEUS: maximum likelihood superpositioning and analysis of macromolecular structures | Q24656525 | ||
| Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones | Q27635195 | ||
| Partial agonists activate PPARgamma using a helix 12 independent mechanism | Q27648786 | ||
| Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method | Q27650591 | ||
| Coupling of receptor conformation and ligand orientation determine graded activity | Q27664921 | ||
| Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma | Q27766012 | ||
| Using NMRView to visualize and analyze the NMR spectra of macromolecules | Q27860567 | ||
| AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading | Q27860652 | ||
| NMRPipe: a multidimensional spectral processing system based on UNIX pipes | Q27860859 | ||
| Overview of nomenclature of nuclear receptors | Q28276106 | ||
| Accurate structural correlations from maximum likelihood superpositions | Q28472205 | ||
| Dynamic personalities of proteins | Q29616723 | ||
| Estrogen receptors: how do they signal and what are their targets | Q29617958 | ||
| A heteronuclear correlation experiment for simultaneous determination of 15N longitudinal decay and chemical exchange rates of systems in slow equilibrium | Q30194094 | ||
| Hydrogen/Deuterium Exchange Reveals Distinct Agonist/Partial Agonist Receptor Dynamics within Vitamin D Receptor/Retinoid X Receptor Heterodimer | Q30497045 | ||
| Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution | Q33304896 | ||
| HD desktop: an integrated platform for the analysis and visualization of H/D exchange data | Q33398917 | ||
| Methods for the Analysis of High Precision Differential Hydrogen Deuterium Exchange Data | Q33884396 | ||
| Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A | Q34024214 | ||
| Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. | Q34330155 | ||
| An introduction to NMR-based approaches for measuring protein dynamics | Q34700484 | ||
| Implications of protein flexibility for drug discovery | Q35167908 | ||
| Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation | Q35230678 | ||
| The nuclear receptor superfamily and drug discovery | Q36558133 | ||
| Unique ligand binding patterns between estrogen receptor alpha and beta revealed by hydrogen-deuterium exchange. | Q37435225 | ||
| NMR analysis of site-specific ligand binding in oligomeric proteins. Dynamic studies on the interaction of riboflavin synthase with trifluoromethyl-substituted intermediates. | Q38355039 | ||
| Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry | Q38485202 | ||
| X-ray crystallography and NMR reveal complementary views of structure and dynamics | Q41648328 | ||
| Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings | Q42152410 | ||
| Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators | Q42237982 | ||
| Rosiglitazone, PPARγ, and type 2 diabetes | Q42536949 | ||
| Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator | Q42805803 | ||
| Obesity: New life for antidiabetic drugs | Q42842891 | ||
| Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state | Q43115788 | ||
| Benzoyl 2-methyl indoles as selective PPARgamma modulators | Q45190005 | ||
| Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping | Q45235950 | ||
| Communication breakdown: protein dynamics and drug design | Q46092021 | ||
| New Insights on the Mechanism of PPAR‐targeted Drugs | Q54633589 | ||
| Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity | Q61697352 | ||
| Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation | Q73675477 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 139-150 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Structure | Q15709970 |
| P1476 | title | Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism | |
| P478 | volume | 20 |
| Q48044188 | A Natural Compound Formononetin Derived From Astragalus Membranaceus Increase Adipocyte Thermogenesis by Modulating PPARγ Activity. |
| Q38435111 | A Residue-Resolved Bayesian Approach to Quantitative Interpretation of Hydrogen-Deuterium Exchange from Mass Spectrometry: Application to Characterizing Protein-Ligand Interactions |
| Q89790880 | A molecular switch regulating transcriptional repression and activation of PPARγ |
| Q58586525 | A structural mechanism for directing corepressor-selective inverse agonism of PPARγ |
| Q43249416 | A structural perspective on nuclear receptors as targets of environmental compounds |
| Q40993997 | Activation helix orientation of the estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. |
| Q38449883 | An alternate binding site for PPARγ ligands |
| Q47608132 | Axonal PPARγ promotes neuronal regeneration after injury |
| Q49433973 | Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor |
| Q28817182 | CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands |
| Q42811249 | Characterization of telmisartan-derived PPARγ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment |
| Q58709352 | Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism |
| Q47130302 | Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ. |
| Q64097677 | Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists |
| Q34337336 | Concerted dynamic motions of an FABP4 model and its ligands revealed by microsecond molecular dynamics simulations |
| Q60937920 | Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ |
| Q41817461 | Couple dynamics: PPARγ and its ligand partners |
| Q26745533 | Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones |
| Q89698157 | Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ |
| Q35737665 | Deconvolution of Complex 1D NMR Spectra Using Objective Model Selection |
| Q92984806 | Defining a Canonical Ligand-Binding Pocket in the Orphan Nuclear Receptor Nurr1 |
| Q55379909 | Defining a conformational ensemble that directs activation of PPARγ. |
| Q92163388 | Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ |
| Q58696993 | Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds |
| Q33823673 | Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease. |
| Q55481649 | Gaussian Accelerated Molecular Dynamics: Theory, Implementation, and Applications. |
| Q37379758 | Graded activation and free energy landscapes of a muscarinic G-protein-coupled receptor |
| Q38245359 | HDX-MS guided drug discovery: small molecules and biopharmaceuticals |
| Q52678835 | Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. |
| Q90448406 | Identification and structural insight of an effective PPARγ modulator with improved therapeutic index for anti-diabetic drug discovery |
| Q37099077 | Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1. |
| Q37609686 | Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro. |
| Q27677013 | Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α |
| Q42110736 | Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors |
| Q38433439 | Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor. |
| Q30152626 | Molecular Dynamics Simulations of apo and holo forms of Fatty Acid Binding Protein 5 and Cellular Retinoic Acid Binding Protein II Reveal Highly Mobile Protein, Retinoic Acid Ligand, and Water Molecules. |
| Q38937075 | Multiple functions and essential roles of nuclear receptor coactivators of bHLH-PAS family |
| Q47111177 | Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes |
| Q42227561 | Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. |
| Q51445412 | PPARγ helix 12 exhibits an antagonist conformation. |
| Q51526335 | PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: a case study. |
| Q37407887 | PPARγ signaling and metabolism: the good, the bad and the future |
| Q88530228 | Peroxisome Proliferator-activated Receptor γ and Mitochondria: Drivers or Passengers on the Road to Pulmonary Hypertension? |
| Q35625043 | Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex |
| Q92935598 | Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies |
| Q38435324 | Probing the Complex Binding Modes of the PPARγ Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy |
| Q57289952 | Protein Conformational Transitions from All-Atom Adaptively Biased Path Optimization |
| Q90702022 | Quantitative structural assessment of graded receptor agonism |
| Q27683572 | Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network |
| Q58919671 | SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated ReceptorγActivators: A Perspective |
| Q49567183 | Screening for PPAR Non-Agonist Ligands Followed by Characterization of a Hit, AM-879, with Additional No-Adipogenic and cdk5-Mediated Phosphorylation Inhibition Properties |
| Q35860302 | Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency |
| Q58699276 | Signaling Mechanisms of Selective PPAR Modulators in Alzheimer's Disease |
| Q36497819 | Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery |
| Q52652410 | Solution Nuclear Magnetic Resonance Studies of the Ligand-Binding Domain of an Orphan Nuclear Receptor Reveal a Dynamic Helix in the Ligand-Binding Pocket. |
| Q90460134 | Structural Basis for the Regulation of PPARγ Activity by Imatinib |
| Q40726727 | Structural and Dynamical Insight into PPARγ Antagonism: In Silico Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists |
| Q35990304 | Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. |
| Q36381221 | Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data. |
| Q27683978 | Structure of REV-ERB Ligand-binding Domain Bound to a Porphyrin Antagonist |
| Q47169300 | Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs |
| Q47825752 | Synergistic Regulation of Coregulator/Nuclear Receptor Interaction by Ligand and DNA. |
| Q40075003 | Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. |
| Q97644598 | The PPAR Ω Pocket: Renewed Opportunities for Drug Development |
| Q57169333 | The nuclear receptor superfamily: A structural perspective |
| Q35055598 | The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2. |
| Q92062464 | To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations |
| Q37411882 | Understanding nuclear receptor form and function using structural biology |
| Q36466200 | Unexpected Allosteric Network Contributes to LRH-1 Co-regulator Selectivity. |
| Q47709745 | Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands |
| Q58091922 | VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity |
Search more.